Black Diamond Therapeutics, Inc.
BDTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.06 | 0.03 | -0.02 |
| FCF Yield | -52.91% | -54.04% | -130.42% | -53.33% |
| EV / EBITDA | -1.49 | -1.08 | -0.64 | -1.23 |
| Quality | ||||
| ROIC | -74.69% | -59.57% | -60.23% | -53.97% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.81 | 0.93 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 6.66% | 21.72% | 17.10% | -96.71% |
| Safety | ||||
| Net Debt / EBITDA | 0.21 | 0.36 | 0.07 | 0.29 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,264.01 | -1,941.10 | -211.58 | -676.16 |